Literature DB >> 8130379

Is the use of chemotherapy justified in non-small-cell lung cancer?

P Kelly1, L Clancy.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8130379     DOI： 10.2165/00002512-199404010-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


× No keyword cloud information.
  52 in total

1.  Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients.

Authors:  A Skarin; M Jochelson; T Sheldon; A Malcolm; P Oliynyk; R Overholt; M Hunt; E Frei
Journal:  J Surg Oncol       Date:  1989-04       Impact factor: 3.454

2.  Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

Authors:  P A Ganz; R A Figlin; C M Haskell; N La Soto; J Siau
Journal:  Cancer       Date:  1989-04-01       Impact factor: 6.860

3.  Age as a risk factor for inadequate treatment.

Authors:  T Wetle
Journal:  JAMA       Date:  1987 Jul 24-31       Impact factor: 56.272

4.  You're never too old.

Authors:  J B Wong; D N Salem; S G Pauker
Journal:  N Engl J Med       Date:  1993-04-01       Impact factor: 91.245

5.  Therapy of stage I and stage II non-small cell lung cancer.

Authors:  C F Mountain
Journal:  Semin Oncol       Date:  1983-03       Impact factor: 4.929

6.  Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study.

Authors:  A Veronesi; M D Magri; U Tirelli; A Carbone; F Mazza; S Franceschi; R Talamini; A Ardizzoni; L Canobbio; R Rosso
Journal:  Am J Clin Oncol       Date:  1988-10       Impact factor: 2.339

Review 7.  Etoposide in the management of non-small cell lung cancer.

Authors:  J C Ruckdeschel
Journal:  Cancer       Date:  1991-01-01       Impact factor: 6.860

Review 8.  Chronic oral etoposide in the treatment of lung cancer.

Authors:  R DeVore; J Hainsworth; F A Greco; K Hande; D Johnson
Journal:  Semin Oncol       Date:  1992-12       Impact factor: 4.929

9.  Inoperable non-small cell lung cancer: radiation with or without chemotherapy.

Authors:  K Mattson; L R Holsti; P Holsti; M Jakobsson; M Kajanti; K Liippo; M Mäntylä; S Niitamo-Korhonen; V Nikkanen; E Nordman
Journal:  Eur J Cancer Clin Oncol       Date:  1988-03

10.  Choice of cancer therapy varies with age of patient.

Authors:  J Samet; W C Hunt; C Key; C G Humble; J S Goodwin
Journal:  JAMA       Date:  1986-06-27       Impact factor: 56.272
View more
  3 in total

Review 1.  Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review.

Authors:  A J Coukell; S Noble; D Faulds
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

Review 3.  The aged patient with lung cancer. Management recommendations.

Authors:  V Zagonel; U Tirelli; D Serraino; G Lo Re; M C Merola; M Mascarin; M G Trovò; A Carbone; S Monfardini
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.